SWOT Analysis of ARNI Anti-Heart Failure Drugs in Chinese Market

Asian Journal of Social Pharmacy ›› 2020, Vol. 15 ›› Issue (3): 139-144.

Previous Articles Next Articles

SWOT Analysis of ARNI Anti-Heart Failure Drugs in Chinese Market

Lv Xin, Chen Yuwen*

School of Business Administration, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China

Online:2020-09-20 Published:2020-09-15
Contact: Chen Yuwen, professor. Major research area: pharmacy administration, new drug research and development, etc. Tel: 024-23986552, E-mail: cywwyc@163.com. E-mail:cywwyc@163.com

Abstract

Abstract: Objective To study the domestic market environment and its advantages and disadvantages of angiotensin receptor-neprilysin inhibitor (ARNI) anti-heart failure drugs so as to provide reference for the promotion of this sort of drugs in Chinese market. Methods Based on SWOT model, the anti-heart failure drugs were analyzed from four aspects: strength, weakness, opportunity and threat. Results and Conclusion ARNI anti-heart failure drugs have greater opportunities than threats in China, and their advantages outweigh the disadvantages. However, in order to gain more market share, it is still necessary to pay attention to the clinical verification of their long-term safety and effectiveness. In addition, consumers are interested in the price of ARNI anti-heart failure drugs and its popularity.

Key words: ARNI, anti-heart failure drugs, heart failure, SWOT analysis

Lv Xin, Chen Yuwen. SWOT Analysis of ARNI Anti-Heart Failure Drugs in Chinese Market[J]. Asian Journal of Social Pharmacy, 2020, 15(3): 139-144.

Trendmd

[1]	Xiu Yu, Wang Shuling. Investigation and Countermeasures of the Development of Chinese Pharmaceutical E-commerce in the B2C Model Based on PEST-SWOT Analysis [J]. Asian Journal of Social Pharmacy, 2023, 18(4): 398-405.
[2]	Jiang Yang, Yang Yue. Study on the Changes of FDA Finished Pharmaceuticals Warning Letters between 2011 and 2021 [J]. Asian Journal of Social Pharmacy, 2022, 17(4): 291-299.
[3]	Liu Tianchi, Zeng Yu. SWOT Analysis and Countermeasures Study on TCM Industry in Hainan Free Trade Port [J]. Asian Journal of Social Pharmacy, 2021, 16(1): 41-47.
[4]	Fu Geyang, Tian Lijuan. The Analysis of Marketing Strategy of Plendil [J]. Asian Journal of Social Pharmacy, 2020, 15(1): 37-43.
[5]	Fu Yang, Tian Lijuan. SWOT Analysis and Development Suggestions on HK Drugs of G Pharmaceutical Firm [J]. Asina Journal Of Social Pharmacy, 2019, 14(2): 55-58.
[6]	Jin Quanyuan, Lin Xiaohui, Dong Li. Patent Early Warning Mechanism in Pharmaceutical Universities in China [J]. Asina Journal Of Social Pharmacy, 2018, 13(3): 86-92.
[7]	ZHAO Pin;YANG Yue. FDA Warning Letter System and Its Enlightenment to China [J]. , 2015, 10(2): 61-65.
[8]	HAN Xue-ting;HUANG Zhe. Study on O2O Pharmacy E-commerce Based on SWOT Analysis [J]. , 2015, 10(2): 97-101.
[9]	BAI Jian;;DAI Juan;LI Ye. Diagnostic Reagent Industry in China: SWOT Analysisand Countermeasures [J]. , 2014, 9(3): 119-123.
[10]	DONG Hong-nian;HUANG Tai-kang. Health Reform in China and America: A Comparative Study [J]. , 2012, 7(3): 137-141.
[11]	ZHAO Ying-huan;WANG Dan;CHENG Xiu-ge;XU Dong-jia;WANG Yan-chun;CANG Ai-jun. Drug Safety and the Construction of Early Warning System on Drug [J]. , 2011, 6(2): 79-83.
[12]	YANG Min;LI Ye;FU Fei;YAN Shuang-shuang. Current Status of Cardiovascular Drug Market and Enterprises’ Future Development Strategy in China [J]. , 2011, 6(2): 96-99.
[13]	LIU Jing;LIU Yu-jun. Analysis on FDA’s cGMP Warning Letters for Medical Products [J]. , 2007, 2(4): 173-177.

Asian Journal Of Social Pharmacy

SWOT Analysis of ARNI Anti-Heart Failure Drugs in Chinese Market

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Recommended Articles

Metrics

Comments